U.S. Pharma-Bio Industry Home to $28 Billion in ESG Projects Under Construction
Industries across the U.S. continue to implement environmental, social and governance (ESG) initiatives, and the Pharmaceutical-Biotech Industry is no exception. The industry's ESG-related projects are buoyed by adherence to Leadership in Energy and Environmental Design (LEED) guidelines that ensure facilities are built with a multitude of "green" features.